UBX-1325 is an investigational drug being developed for the treatment of retinal diseases, such as age-related macular degeneration (AMD) and diabetic macular edema (DME). It is a small molecule that works by targeting and inhibiting the protein BCL-2, which plays a role in cell survival. By modulating this pathway, UBX-1325 aims to promote the clearance of damaged cells and reduce inflammation in the retina, potentially improving vision outcomes.
MedKoo Cat#: 145704
Name: UBX-1325
CAS#: 2271269-01-1
Chemical Formula: C53H59ClF3N6O10PS3
Exact Mass: 1158.2800
Molecular Weight: 1159.69
Elemental Analysis: C, 54.89; H, 5.13; Cl, 3.06; F, 4.91; N, 7.25; O, 13.80; P, 2.67; S, 8.29
The following data is based on the product molecular weight 1,159.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
